Cargando…

Decreased Tertiary Lymphoid Structures in Lung Adenocarcinomas with ALK Rearrangements

Purpose: This study sought to characterize the tumor immune microenvironment (TIME) of lung adenocarcinomas with ALK rearrangements (ALK+ LUAD), which responds poorly to immune checkpoint inhibitors (ICIs) therapy. Materials and methods: Immune score evaluation and immunohistochemical (IHC) validati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zou, Yi, Zhao, Jing, Huang, Fengbo, Xiang, Xueping, Xia, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572246/ https://www.ncbi.nlm.nih.gov/pubmed/36233802 http://dx.doi.org/10.3390/jcm11195935

Ejemplares similares

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
por: Cha, Yoon Jin, et al.
Publicado: (2016)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
por: Imanishi, Naoko, et al.
Publicado: (2018)

Response to ALK‐TKIs in a lung adenocarcinoma patient harboring dual DCTN1‐ALK and ALK‐CLIP4 rearrangements
por: Gao, Fangfang, et al.
Publicado: (2022)

Tertiary lymphoid structures in lung adenocarcinoma: characteristics and related factors
por: Ren, Fangping, et al.
Publicado: (2022)

NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
por: Cao, Qi, et al.
Publicado: (2019)

Thyroid metastasis from lung adenocarcinoma with EML4-ALK rearrangement
por: Kawamoto, Hironori, et al.
Publicado: (2016)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

Frequency of ALK Rearrangement by FISH Testing and its Correlation with ALK-IHC in Adenocarcinoma of Primary Lung Origin
por: Moatter, Samar, et al.
Publicado: (2018)

TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations
por: Ouseph, Madhu M, et al.
Publicado: (2019)

Tertiary lymphoid structure and decreased CD8(+) T cell infiltration in minimally invasive adenocarcinoma
por: Wang, Jin, et al.
Publicado: (2022)

Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report
por: Fan, Jun, et al.
Publicado: (2020)

CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma
por: An, Rong, et al.
Publicado: (2016)

Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma
por: Marino, Federica Zito, et al.
Publicado: (2015)

Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung
por: Balla, Agnes, et al.
Publicado: (2018)

CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas
por: Woo, Jung Han, et al.
Publicado: (2020)

Genomic and Transcriptomic Analysis of Neuroendocrine Transformation in ALK-Rearranged Lung Adenocarcinoma After Treatments With Sequential ALK Inhibitors: A Brief Report
por: Huang, Jie, et al.
Publicado: (2022)

Correction: Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma
por: Zito Marino, Federica, et al.
Publicado: (2015)

Frequencies of ALK rearrangements in lung adenocarcinoma subtypes: a study of 2299 Chinese cases
por: Yu, Yongfeng, et al.
Publicado: (2016)

ALK rearrangement in lung adenocarcinoma with concurrent cervix and breast metastases: A case report
por: Chuang, Xin, et al.
Publicado: (2018)

ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma
por: Bi, Rui, et al.
Publicado: (2019)

A case of ALK-rearranged lung adenocarcinoma associated with syndrome of inappropriate antidiuretic hormone
por: Miyashita, Yoshihiro, et al.
Publicado: (2020)

Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma
por: Zhang, Huan, et al.
Publicado: (2021)

ALK ‐rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib
por: Song, Lianxi, et al.
Publicado: (2022)

Characterization of Estrogen Receptors in Pancreatic Adenocarcinoma with Tertiary Lymphoid Structures
por: Zou, Xuan, et al.
Publicado: (2023)

Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements
por: Wu, Shafei, et al.
Publicado: (2015)

Prognostic Significance of Gene Signature of Tertiary Lymphoid Structures in Patients With Lung Adenocarcinoma
por: Feng, Hong, et al.
Publicado: (2021)

ALK-rearranged squamous cell carcinoma of the lung
por: Takanashi, Yusuke, et al.
Publicado: (2015)

ALK‐rearranged squamous cell carcinoma of the lung
por: Meng, Qiyi, et al.
Publicado: (2021)

ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib: A case report
por: Qiu, Ye, et al.
Publicado: (2019)

Ovarian Metastases from ALK-rearranged Lung Adenocarcinoma: A Case Report and Literature Review
por: Sasano, Hajime, et al.
Publicado: (2018)

Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib
por: Zhu, You-Cai, et al.
Publicado: (2019)

Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma
por: Angeles, Arlou Kristina, et al.
Publicado: (2023)

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
por: Rao, Chuangzhou, et al.
Publicado: (2022)

Clinical implications and molecular features of tertiary lymphoid structures in stage I lung adenocarcinoma
por: Xu, Xuejun, et al.
Publicado: (2023)

Clonally‐related primary ALK rearranged adenocarcinoma and associated metastatic lesions
por: Zhu, You‐cai, et al.
Publicado: (2018)

Complex genetic alterations contribute to rapid disease progression in an ALK rearrangement lung adenocarcinoma patient: a case report
por: Long, Xiang, et al.
Publicado: (2021)

Overview of ALK and ROS1 Rearranged Lung Cancer
por: Choi, Chang Min
Publicado: (2013)

Identification and therapeutic evaluation of ALK rearrangements in non‐small‐cell lung cancer
por: Zhao, Ruiying, et al.
Publicado: (2022)

Worse disease-free, tumor-specific, and overall survival in surgically-resected lung adenocarcinoma patients with ALK rearrangement
por: Gao, Qiongqiong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_u2qot888clh8bbqo8keo64oklt